Last reviewed · How we verify
human soluble insulin
human soluble insulin is a Insulin Small molecule drug developed by Novo Nordisk A/S. It is currently FDA-approved for Type 1 diabetes mellitus, Type 2 diabetes mellitus.
Human soluble insulin binds to insulin receptors on cells to promote glucose uptake and utilization, lowering blood glucose levels.
Human soluble insulin is a protein that acts as an agonist to the insulin receptor, stimulating its activity. It is used to treat conditions such as Type 1 Diabetes Mellitus, Type 2 Diabetes Mellitus, and Ovarian Neoplasms, among others.
At a glance
| Generic name | human soluble insulin |
|---|---|
| Sponsor | Novo Nordisk A/S |
| Drug class | Insulin |
| Target | Insulin receptor |
| Modality | Small molecule |
| Therapeutic area | Diabetes |
| Phase | FDA-approved |
Mechanism of action
Insulin is a naturally occurring hormone that regulates blood glucose by binding to insulin receptors on muscle, fat, and liver cells, facilitating glucose transport into these cells and promoting its storage as glycogen or conversion to fat. This mechanism mimics the body's endogenous insulin response to maintain normal blood glucose homeostasis. Human soluble insulin is a rapid-acting formulation designed for subcutaneous injection to manage hyperglycemia in diabetic patients.
Approved indications
- Type 1 diabetes mellitus
- Type 2 diabetes mellitus
Common side effects
- Hypoglycemia
- Injection site reactions
- Weight gain
- Lipodystrophy
Key clinical trials
- Epigenetic Regulation of Human Adipose Tissue Distribution (NA)
- The Importance of Insulin Action in the Brain for the Immune System During Physical Activity-Overweight (NA)
- Pancreatic Islet Transplantation Into the Anterior Chamber of the Eye (PHASE1, PHASE2)
- Cadisegliatin as Adjunctive Therapy to Insulin in Participants With Type 1 Diabetes (PHASE3)
- PROCHYMAL® (Human Adult Stem Cells) for the Treatment of Recently Diagnosed Type 1 Diabetes Mellitus (T1DM) (PHASE2)
- Effect of Topical Insulin on Healing Rate of Pemphigus Lesions (PHASE2)
- Taste Bud-Derived Stem Cells in Humans
- Comparison of the Pharmacokinetics (PK) and Pharmacodynamics (PD) Biosimilarity of Proposed Biosimilar Rapid-Acting Insulin Aspart (I004) and NovoLog After Single-Dose Subcutaneous Administration to Healthy Volunteers (PHASE2, PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- human soluble insulin CI brief — competitive landscape report
- human soluble insulin updates RSS · CI watch RSS
- Novo Nordisk A/S portfolio CI
Frequently asked questions about human soluble insulin
What is human soluble insulin?
How does human soluble insulin work?
What is human soluble insulin used for?
Who makes human soluble insulin?
What drug class is human soluble insulin in?
What development phase is human soluble insulin in?
What are the side effects of human soluble insulin?
What does human soluble insulin target?
Related
- Drug class: All Insulin drugs
- Target: All drugs targeting Insulin receptor
- Manufacturer: Novo Nordisk A/S — full pipeline
- Therapeutic area: All drugs in Diabetes
- Indication: Drugs for Type 1 diabetes mellitus
- Indication: Drugs for Type 2 diabetes mellitus
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing